Alpha Cognition’s 2Q26 results showed continued expansion of the ZUNVEYL launch, with net product revenue increasing 71% q/q to $6.0M as bottles dispensed increased 37% to 8,294 and repeat prescribers increased 29% to 1,024. Commercial momentum occurred while downstream PBM implementation remained approximately 16%, with management indicating that demand growth continued into 3Q without additional formulary wins. The evidence-generation program also continues to advance, with CONVERGE data expected in 3Q26 and RESOLVE underway, while the sublingual program remains dependent on results from a comparative PK study. Management reduced FY26 R&D and SG&A guidance to $50M-$54M and continues to target operating profitability in 2027.